Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955852486> ?p ?o ?g. }
- W2955852486 endingPage "CT059" @default.
- W2955852486 startingPage "CT059" @default.
- W2955852486 abstract "Abstract Background: HER2/neu is overexpressed in 15-25% of gastric cancer patients and associated with poor prognosis. Alternative treatments to monoclonal antibodies are needed due to cost and global availability issues of mAbs. Thus a B-cell peptide vaccine (IMU-131) was developed, consisting of 3 fused B-cell epitopes (p467) from the HER2/neu extracellular domain coupled to CRM197 applied with the adjuvant Montanide. The current study evaluated the optimal and safe vaccine dose leading to immunogenicity and clinical responses. Material & Methods: In an open-label multicenter Phase Ib trial in SE-Asia and Eastern Europe, 14 patients with HER2/neu overexpressing (++/+++) gastric or gastroesophageal junction adenocarcinoma were recruited to receive 3 injections of IMU-131 (days 0, 14, 35) in combination with chemotherapy (CT) every 21 days. Dose escalation with 10 µg, 30 µg and 50 µg was performed in 3 cohorts. Safety, immunogenicity and clinical responses were evaluated. Results: No SAEs related to administration of IMU-131 were reported. Eleven of 14 patients were evaluable for vaccine-specific immune responses and 10 for tumor growth assessment. Higher p467- and Her-2 specific IgG levels were observed in cohort 2 (30 µg/dose) compared to cohort 1 (10 µg/dose). Two of five patients in cohort 2 showed minimal antibody titers. In contrast, all patients in cohort 3 (50µg/dose) responded to the vaccine with equally high antibody levels. Response rate was an exploratory endpoint and of 10 evaluable patients, 5 patients showed partial response and 4 patients showed stable disease. In cohort 3 the high antibody levels correlated with clinical response, while in cohort 2 only moderate correlations between humoral and clinical responses were observed. In cohort 1 partial response did not correlate with Ab levels, but rather with a high percentage of CD8 T-cells and increased inflammatory cytokine levels (high IFN-γ and TNF-α/IL-10 ratio). Conclusions: The vaccine was well tolerated and safe with antibody responses at the highest dose (50 µg) showing a strong correlation with clinical responses. Thus, a dose of 50 µg was recommended for further evaluation in Phase II, featuring two arms of either IMU 131 plus CT or CT alone. We propose that this vaccine might be of significant medical benefit and further trials are warranted. Citation Format: Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, Iurie Bulat, Arunee Dechaphunkul, Wichit Arpornwirat, Chaiyut Charoentum, Chia-Jui Yen, Thomas Cheung Yau, Marina Maglakelidze, Suebpong Tanasanvimon, Jedzada Maneechavakajorn, Aumkhae Sookprasert, Li-Yuan Bai, Wen-Chi Chou, Teerapat Ungtrakul, Christoph C. Zielinski, Leslie Chong, Nick Ede, Anthony J Good. A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT059." @default.
- W2955852486 created "2019-07-12" @default.
- W2955852486 creator A5004447476 @default.
- W2955852486 creator A5004548381 @default.
- W2955852486 creator A5007216895 @default.
- W2955852486 creator A5011730639 @default.
- W2955852486 creator A5023630854 @default.
- W2955852486 creator A5026090288 @default.
- W2955852486 creator A5027932918 @default.
- W2955852486 creator A5028950420 @default.
- W2955852486 creator A5033329129 @default.
- W2955852486 creator A5035852624 @default.
- W2955852486 creator A5041880936 @default.
- W2955852486 creator A5048367683 @default.
- W2955852486 creator A5049829812 @default.
- W2955852486 creator A5052358350 @default.
- W2955852486 creator A5053390754 @default.
- W2955852486 creator A5068495326 @default.
- W2955852486 creator A5069961709 @default.
- W2955852486 creator A5077961608 @default.
- W2955852486 creator A5083271407 @default.
- W2955852486 creator A5087683383 @default.
- W2955852486 date "2019-07-01" @default.
- W2955852486 modified "2023-09-27" @default.
- W2955852486 title "Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach" @default.
- W2955852486 doi "https://doi.org/10.1158/1538-7445.am2019-ct059" @default.
- W2955852486 hasPublicationYear "2019" @default.
- W2955852486 type Work @default.
- W2955852486 sameAs 2955852486 @default.
- W2955852486 citedByCount "0" @default.
- W2955852486 crossrefType "journal-article" @default.
- W2955852486 hasAuthorship W2955852486A5004447476 @default.
- W2955852486 hasAuthorship W2955852486A5004548381 @default.
- W2955852486 hasAuthorship W2955852486A5007216895 @default.
- W2955852486 hasAuthorship W2955852486A5011730639 @default.
- W2955852486 hasAuthorship W2955852486A5023630854 @default.
- W2955852486 hasAuthorship W2955852486A5026090288 @default.
- W2955852486 hasAuthorship W2955852486A5027932918 @default.
- W2955852486 hasAuthorship W2955852486A5028950420 @default.
- W2955852486 hasAuthorship W2955852486A5033329129 @default.
- W2955852486 hasAuthorship W2955852486A5035852624 @default.
- W2955852486 hasAuthorship W2955852486A5041880936 @default.
- W2955852486 hasAuthorship W2955852486A5048367683 @default.
- W2955852486 hasAuthorship W2955852486A5049829812 @default.
- W2955852486 hasAuthorship W2955852486A5052358350 @default.
- W2955852486 hasAuthorship W2955852486A5053390754 @default.
- W2955852486 hasAuthorship W2955852486A5068495326 @default.
- W2955852486 hasAuthorship W2955852486A5069961709 @default.
- W2955852486 hasAuthorship W2955852486A5077961608 @default.
- W2955852486 hasAuthorship W2955852486A5083271407 @default.
- W2955852486 hasAuthorship W2955852486A5087683383 @default.
- W2955852486 hasConcept C121608353 @default.
- W2955852486 hasConcept C126322002 @default.
- W2955852486 hasConcept C143998085 @default.
- W2955852486 hasConcept C159654299 @default.
- W2955852486 hasConcept C195616568 @default.
- W2955852486 hasConcept C197934379 @default.
- W2955852486 hasConcept C203014093 @default.
- W2955852486 hasConcept C203092338 @default.
- W2955852486 hasConcept C2776694085 @default.
- W2955852486 hasConcept C2776789287 @default.
- W2955852486 hasConcept C2777863537 @default.
- W2955852486 hasConcept C2777909004 @default.
- W2955852486 hasConcept C2778375690 @default.
- W2955852486 hasConcept C2780868878 @default.
- W2955852486 hasConcept C31760486 @default.
- W2955852486 hasConcept C526805850 @default.
- W2955852486 hasConcept C535046627 @default.
- W2955852486 hasConcept C71924100 @default.
- W2955852486 hasConcept C72563966 @default.
- W2955852486 hasConcept C90924648 @default.
- W2955852486 hasConceptScore W2955852486C121608353 @default.
- W2955852486 hasConceptScore W2955852486C126322002 @default.
- W2955852486 hasConceptScore W2955852486C143998085 @default.
- W2955852486 hasConceptScore W2955852486C159654299 @default.
- W2955852486 hasConceptScore W2955852486C195616568 @default.
- W2955852486 hasConceptScore W2955852486C197934379 @default.
- W2955852486 hasConceptScore W2955852486C203014093 @default.
- W2955852486 hasConceptScore W2955852486C203092338 @default.
- W2955852486 hasConceptScore W2955852486C2776694085 @default.
- W2955852486 hasConceptScore W2955852486C2776789287 @default.
- W2955852486 hasConceptScore W2955852486C2777863537 @default.
- W2955852486 hasConceptScore W2955852486C2777909004 @default.
- W2955852486 hasConceptScore W2955852486C2778375690 @default.
- W2955852486 hasConceptScore W2955852486C2780868878 @default.
- W2955852486 hasConceptScore W2955852486C31760486 @default.
- W2955852486 hasConceptScore W2955852486C526805850 @default.
- W2955852486 hasConceptScore W2955852486C535046627 @default.
- W2955852486 hasConceptScore W2955852486C71924100 @default.
- W2955852486 hasConceptScore W2955852486C72563966 @default.
- W2955852486 hasConceptScore W2955852486C90924648 @default.
- W2955852486 hasIssue "13_Supplement" @default.
- W2955852486 hasLocation W29558524861 @default.
- W2955852486 hasOpenAccess W2955852486 @default.
- W2955852486 hasPrimaryLocation W29558524861 @default.
- W2955852486 hasRelatedWork W112819031 @default.
- W2955852486 hasRelatedWork W1968036257 @default.
- W2955852486 hasRelatedWork W2087736549 @default.